Halia Therapeutics Appoints Gary Sabin as Executive Chairman and Adds Three Independent Directors to Board

Industry leaders join at a pivotal moment as company advances HT-6184 toward a pivotal trial in MDS and prepares Phase 2a initiation for HT-4253 in Alzheimer's disease LEHI, Utah, May 19, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., The Genetic Resilience Company™, a clinical-stage...